Zymeworks, Inc. (ZYME)
28.27
-0.74
(-2.55%)
USD |
NASDAQ |
Aug 28, 16:00
27.87
-0.40
(-1.41%)
After-Hours: 20:00
Zymeworks Cash from Operations (Quarterly) : -31.59M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -31.59M |
| March 31, 2026 | -45.72M |
| December 31, 2025 | -9.979M |
| September 30, 2025 | -31.91M |
| June 30, 2025 | 12.23M |
| March 31, 2025 | -3.407M |
| December 31, 2024 | -39.45M |
| September 30, 2024 | -6.053M |
| June 30, 2024 | -24.55M |
| March 31, 2024 | -37.68M |
| December 31, 2023 | 15.58M |
| September 30, 2023 | -42.91M |
| June 30, 2023 | -6.716M |
| March 31, 2023 | -83.19M |
| December 31, 2022 | 318.20M |
| September 30, 2022 | -70.21M |
| June 30, 2022 | -54.38M |
| March 31, 2022 | -55.41M |
| December 31, 2021 | -50.09M |
| Date | Value |
|---|---|
| September 30, 2021 | -48.74M |
| June 30, 2021 | -51.77M |
| March 31, 2021 | -40.80M |
| December 31, 2020 | -50.95M |
| September 30, 2020 | -18.73M |
| June 30, 2020 | -48.68M |
| March 31, 2020 | -37.49M |
| December 31, 2019 | -36.44M |
| September 30, 2019 | -11.33M |
| June 30, 2019 | -13.21M |
| March 31, 2019 | -21.30M |
| December 31, 2018 | 49.26M |
| September 30, 2018 | -12.55M |
| June 30, 2018 | 4.592M |
| March 31, 2018 | -17.57M |
| December 31, 2017 | 40.76M |
| September 30, 2017 | -14.10M |
| June 30, 2017 | -13.74M |
| March 31, 2017 | -12.70M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Theravance Biopharma, Inc. | -6.965M |
| BridgeBio Pharma, Inc. | -71.10M |
| Aprea Therapeutics, Inc. | -3.206M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 16.67M |
| Cash from Financing (Quarterly) | -50.62M |
| Free Cash Flow | -120.53M |
| Free Cash Flow Per Share (Quarterly) | -0.4327 |
| Free Cash Flow to Equity (Quarterly) | -36.68M |
| Free Cash Flow to Firm (Quarterly) | -25.03M |
| Free Cash Flow Yield | -5.71% |